Publication:
Optimizing assessment of CD30 expression in Hodgkin lymphoma by controlling for low expression

Simple item page
dc.contributor.authorSarwar, Shoib
dc.contributor.authorTome, Margaret E.
dc.contributor.authorBillheimer, Dean
dc.contributor.authorSpier, Catherine
dc.contributor.authorSmith, Catharine L
dc.contributor.authorPersky, Daniel
dc.contributor.authorSchmelz, Monika
dc.date.accessioned2024-02-07T09:16:22Z
dc.date.available2024-02-07T09:16:22Z
dc.date.issued2024
dc.description.abstractSince the approval of brentuximab vedotin (BV), assessment of CD30 status by immunohistochemistry gained increasing importance in the clinical management of patients diagnosed with CD30expressing lymphomas, including classical Hodgkin lymphoma (CHL). Paradoxically, patients with low or no CD30 expression respond to BV. This discrepancy may be due to lack of standardization in CD30 staining methods. In this study, we examined 29 cases of CHL and 4 cases of nodular lymphocyte-predominant Hodgkin lymphoma (NLPHL) for CD30 expression using a staining protocol that was designed to detect low CD30 expression levels, and an evaluation system similar to the Allred scoring system used for breast cancer evaluation. For CHL, 10% of cases had low scores and 3% were CD30 negative, with 3 cases in which the majority of tumor cells showed very weak staining. Unexpectedly, one of four cases of NLPHL was positive. We demonstrate intra-patient heterogeneity in CD30 expression levels and staining patterns in tumor cells. Three CHL cases with weak staining may have been missed without the use of control tissue for low expression. Thus, standardization of CD30 immunohistochemical staining with use of known lowexpressing controls may aid in proper CD30 assessment and subsequent therapeutic stratification of patients.es
dc.formatapplication/pdfes
dc.format.extent13es
dc.identifier.citationHistology and Histopathology Vol. 39, nº3 (2024)
dc.identifier.doihttps://doi.org/10.14670/HH-18-644
dc.identifier.issn0213-3911
dc.identifier.issn1699-5848
dc.identifier.urihttp://hdl.handle.net/10201/138840
dc.languageenges
dc.publisherUniversidad de Murcia, Departamento de Biologia Celular e Histiologiaes
dc.relationSin financiación externa a la Universidades
dc.rightsinfo:eu-repo/semantics/openAccesses
dc.rightsAttribution-NonCommercial-NoDerivatives 4.0 Internacional*
dc.rights.urihttp://creativecommons.org/licenses/by-nc-nd/4.0/*
dc.subjectHodgkin lymphomaes
dc.subjectReed Sternberg cellses
dc.subjectCD30es
dc.subjectImmunohistochemistryes
dc.subjectMembrane staininges
dc.subjectCytoplasmic punctate staininges
dc.subjectMembrane traffickinges
dc.subject.otherCDU::6 - Ciencias aplicadas::61 - Medicina::616 - Patología. Medicina clínica. Oncologíaes
dc.titleOptimizing assessment of CD30 expression in Hodgkin lymphoma by controlling for low expressiones
dc.typeinfo:eu-repo/semantics/articlees
dspace.entity.typePublicationes
Files
Original bundle
Now showing 1 - 1 of 1
Thumbnail Image
Name:
3841b756-d0e0-4460-8f39-477039e18881-4.pdf
Size:
8.68 MB
Format:
Adobe Portable Document Format
Description:
Download
License bundle
Now showing 1 - 1 of 1
Thumbnail Image
Name:
license.txt
Size:
2.26 KB
Format:
Item-specific license agreed upon to submission
Description:
Download
Collections
Histology and histopathology Vol.39, nº3 (2024)